m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05560
 [1]
m6A modification AGAP2-AS1 AGAP2-AS1 METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA AGAP2-AS1 miR-424-5p  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target LOC10013.776 (AGAP2-AS1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator LOC10013.776 (AGAP2-AS1) LncRNA View Details
Regulated Target hsa-miR-424-5p View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL3 resulted in the upregulation of AGAP2-AS1 in psoriasis. LOC10013.776 (AGAP2-AS1) is upregulated in the skin tissue of psoriasis patients and m6A methylation was involved in its upregulation. AGAP2-AS1 functioned as a competitive endogenous RNA by sponging hsa-miR-424-5p to upregulate AKT3, activate AKT/mTOR pathway, as well as promote cell proliferation in keratinocytes.
Responsed Disease Psoriasis ICD-11: EA90
 Disease Info 
Pathway Response PI3K-Akt signaling pathway hsa04151
mTOR signaling pathway hsa04150
Cell Process Cell proliferation
Cell apoptosis
In-vitro Model
 HaCaT Normal Homo sapiens CVCL_0038
NHEK (Normal human epithelial keratinocytes)
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
EA90: Psoriasis 166 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Teriparatide Discontinued in Phase 2 [2]
Synonyms
Forteo; Forteo (TN); Teriparatide (genetical recombination); Teriparatide (USAN/INN); Teriparatide (genetical recombination) (JAN)
    Click to Show/Hide
External Link
CID: 16133850
TTD: D0YA2L
 Compound Name Ponesimod Phase 2 [3]
Synonyms
854107-55-4; UNII-5G7AKV2MKP; 5G7AKV2MKP; CHEMBL1096146; Ponesimod [USAN:INN]; Ponesimod,ACT-128800; Ponesimod (ACT-128800); GTPL9320; SCHEMBL15477937; SCHEMBL15477934; DTXSID50234631; MolPort-035-681-391; MolPort-046-033-541; EX-A1417; ZINC34509627; s8241; BDBM50316768; AKOS022180266; DB12016; Compound 8bo [PMID:20446681]; HY-10569; KB-72962; AS-35140; AJ-89002; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-
    Click to Show/Hide
External Link
CID: 11363176
TTD: D0Y4SI
DrugBank: DB12016
 Compound Name Spesolimab Approved [4]
External Link
TTD: D0W9YW
 Compound Name Lestaurtinib Approved (orphan drug) [5]
Synonyms
A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)
    Click to Show/Hide
External Link
CID: 126565
TTD: D0V9WF
DrugBank: DB06469
 Compound Name Belumosudil Approved [6]
External Link
CID: 11950170
TTD: D0U5UC
 Compound Name Deucravacitinib Approved [7]
External Link
CID: 134821691
TTD: D0S1XX
 Compound Name Dithranol Approved [8]
Synonyms
Anthralin; Micanol; Dithranol cream (Crystalip); Dithranol cream (Crystalip), Bioglan
    Click to Show/Hide
External Link
CID: 2202
TTD: D0QO7H
DrugBank: DB11157
 Compound Name Ciclosporin Approved [9]
Synonyms
Cyclosporine A; CSA; Antibiotic S 7481F1; BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; C 3662; CB-01-09 MMX; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); Cicloral (TN); Ciclosporin (JP15); Cipol N; Cipol-N; Consupren; Consupren S; CsA & IFN-alpha; Cyclokat; Cyclophorine; Cyclosporin; Cyclosporin A; Cyclosporin A & IFN-alpha; Cyclosporin A Implant; Cyclosporin A, Tolypocladium inflatum; Cyclosporine (USP); Cyclosporine [USAN]; DE-076; Equoral; From Tolypocladium inflatum (Trichoderma polysporin); GNF-Pf-2808; Gengraf; Gengraf (TN); Helv Chim Acta 60: 1568 (1977); Mitogard; Modusik-A; Neoplanta; Neoral; Neoral (TN); NeuroSTAT; Nova-22007; OL 27-400; OL-27400; OLO-400; Papilock; Pulminiq; RamihyphinA; Restasis; Restasis (TN); S-Neoral; SDZ-OXL 400; ST-603; Sandimmun; Sandimmun Neoral; Sandimmune; Sandimmune (TN); Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine; Sang-2000; Sang-35; SangCyA; Sigmasporin; Sigmasporin Microoral; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); Vekacia; Zyclorin
    Click to Show/Hide
External Link
CID: 24883466
TTD: D0O3YF
 Compound Name Xp-828l Approved [8]
Synonyms
Dermylex (TN)
    Click to Show/Hide
External Link
TTD: D0N1NE
 Compound Name Voclosporin Phase 3 [10]
Synonyms
Luveniq; ISAtx-247; ISA-247; UNII-2PN063X6B1; ISATX247; 515814-01-4; ISA247; 2PN063X6B1; ISA 247; trans-ISA-247; LX211; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; Voclera; 3odi; LX-211; LX-214; ISA247, Luveniq; AC1OCFHS; R-1524; SCHEMBL12632344; CHEBI:135957; (E)-ISA-247; DB11693; 515814-00-3; HY-106638; CS-0026210; D09033; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; 368455-04-3; Voclosporin [USAN]; R 1524; Trans-ISA 247; TrkA-IgG
    Click to Show/Hide
External Link
CID: 6918486
TTD: D0L9HX
DrugBank: DB11693
 Compound Name Verteporfin Approved [8]
Synonyms
Visudyne (TN)
    Click to Show/Hide
External Link
CID: 11980904
TTD: D0I3XG
 Compound Name Mirikizumab Approved [6]
External Link
TTD: D0E7QB
 Compound Name Tazarotene Approved [11]
Synonyms
Avage; Suretin; Tazaroteno; Tazarotenum; Tazorac; Tazoral; Zorac; AGN 190168; AGN-190168; Avage (TN); Tazarotene [USAN:INN]; Tazorac (TN); Zorac (TN); Tazarotene (JAN/USAN/INN); Tazorac, Avage, Zora, Tazarotene; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; Ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester
    Click to Show/Hide
External Link
CID: 5381
TTD: D0BM5G
DrugBank: DB00799
 Compound Name Ustekinumab Phase 3 [12]
Synonyms
6,6-Dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine; WR99210; WR-99210; 47326-86-3; BRN 0629517; WR 99210; 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-; WR-99,210; CHEMBL129788; BRL 6231; 1,6-Dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)-propoxy)-1,3,5-triazine-2 ,4-diamine; 1-(2',4',5'-Trichlorophenoxypropoxy)-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine; Stelara (TN)
    Click to Show/Hide
External Link
TTD: D0A2UV
 Compound Name Azaribine Approved [8]
Synonyms
Triazure; Triacetyl-6-azauridine; Azaribinum; Azaribina; 2169-64-4; 6-Azaribine; TA-Azur; Azaribin; 2',3',5'-Tri-O-acetyl-6-azauridine; 6-Azauridine triacetate; 6-Azauridin-triacetat; 6-Azauridine 2',3',5'-triacetate; Azaribinum [INN-Latin]; 6-AzUR-TA; Azaribina [INN-Spanish]; 2',3',5'-Triacetyl-6-azauridine; CB-304; UNII-K1U80DO9EB; 6-Azauracilribosid-triacetat; K1U80DO9EB; Azaribine [USAN:INN:BAN]; MLS000069488; EINECS 218-515-6; Azauridine triacetate; 2-beta-D-Ribofuranosyl-as-triazine-3,5(2H,4H)-dione 2',3',5'-triace
    Click to Show/Hide
External Link
CID: 16574
TTD: D09SIK
 Compound Name Ammoniated mercury Approved [8]
Synonyms
White precipitate; Mercuric chloride, ammoniated; Mercury ammoniated; Ammoniated mercuric chloride; Mercury, ammoniated; Aminomercury chloride; Aminomercuric chloride; Hydrargyrum ammoniatum; Mercury amine chloride; MERCURIC AMMONIUM CHLORIDE; White mercuric precipitate; White mercury precipitated; Quecksilber(II)-amid-chlorid; Hydrargyrum precipitatum album; Hydrargyrum praecipitatum album; UNII-JD546Z56F0; Mercury(II) chloride ammonobasic; Mercury, ammonobasic (HgNH2Cl); HSDB 1175; JD546Z56F0; EINECS 233-3
    Click to Show/Hide
External Link
CID: 3032553
TTD: D08YPZ
DrugBank: DB13344
 Compound Name Tacalcitol Approved [13]
Synonyms
Bonalfa (TN)
    Click to Show/Hide
External Link
CID: 5283734
TTD: D08SVH
DrugBank: DB13689
 Compound Name Methoxsalen Approved [14]
Synonyms
Ammodin; Ammoidin; Deltasoralen; Dermox; Geroxalen; Meladinin; Meladinina; Meladinine; Meladoxen; Meloxine; Methoxalen; Methoxaten; Oxoralen; Oxsoralen; Oxypsoralen; Puvalen; Puvamet; Ultramop; Uvadex; XANTHOTOXIN; Xanthotoxine; Zanthotoxin; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Dermatech Brand of Methoxsalen; Galderma Brand of Methoxsalen; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen plus ultraviolet radiation; Mex America Brand of Methoxsalen; Oxsoralen Ul tra; Oxsoralen Ultra; Oxsoralen lotion; Sanofi Synthelabo Brand of Methoxsalen; Ultra Mop; Ultramop Lotion; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; X0009; An 8-methoxyfurocoumarin; Meladinin (VAN); Methoxa-Dome; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Methoxsalen [BAN:JAN]; Methoxsalen with ultra-violet A theraphy; Mex-America Brand of Methoxsalen; New-Meladinin; O-methylxanthotoxol; OXSORALEN (TN); Oxsoralen-ultra; Proralone-mop; Psoralen-mop; Psoralon-MOP; Sanofi-Synthelabo Brand of Methoxsalen; Methoxsalen (JP15/USP); Methoxy-8-psoralen; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; 7-Furocoumarin; 8 Methoxypsoralen; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8-MOP; 8-Methoxy; 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxy-(furano-3'.2':6.7-coumarin); 8-Methoxy-2',3',6,7-furocoumarin; 8-Methoxy-4',5',6,7-furocoumarin; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-[furano-3'.2':6.7-coumarin]; 8-Methoxyfuranocoumarin; 8-Methoxypsoralen; 8-Methoxypsoralen with ultraviolet A therapy; 8-Methoxypsoralene; 8-methoxyfuranocoumarins; 8-methoxyfurocoumarins; 8MO; 8MOP; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxypsoralen; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; 9-methoxyfuro[3,2-g]chromen-7-one
    Click to Show/Hide
External Link
CID: 4114
TTD: D08SKH
DrugBank: DB00553
 Compound Name Valrubicin Approved [8]
Synonyms
Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester
    Click to Show/Hide
External Link
CID: 454216
TTD: D07IPB
DrugBank: DB00385
 Compound Name Apremilast Approved [15]
Synonyms
Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
    Click to Show/Hide
External Link
CID: 11561674
TTD: D07ESC
DrugBank: DB05676
 Compound Name Acitretin Approved [16]
Synonyms
Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
    Click to Show/Hide
External Link
CID: 5284513
TTD: D05QDC
DrugBank: DB00459
 Compound Name Brodalumab Approved [17]
Synonyms
AMG 827
    Click to Show/Hide
External Link
TTD: D05CEO
 Compound Name Coal tar Approved [8]
External Link
TTD: D03YET
 Compound Name Efalizumab Approved [18]
Synonyms
Raptiva; Raptiva (TN); Efalizumab (USAN/INN)
    Click to Show/Hide
External Link
TTD: D03SGR
 Compound Name Tapinarof Approved [19]
Synonyms
GSK-2894512
    Click to Show/Hide
External Link
CID: 6439522
TTD: D03DMB
DrugBank: DB06083
 Compound Name Calcipotriol Approved [20]
Synonyms
Calcipotriene; Divonex; Dovonex; BMS-181161; Daivonex (TN); Dovonex (TN); MC-903; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL; 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3
    Click to Show/Hide
External Link
CID: 5288783
TTD: D01QUS
DrugBank: DB02300
 Compound Name NPS-31807 Phase 4 [21]
Synonyms
PP-05; TNF alpha modulator (inflammation), Piramal Life Sciences; TNF alpha modulator (inflammation), NPIL Research & Development
    Click to Show/Hide
External Link
TTD: D0S0ST
 Compound Name LEO 80185 Phase 4 [22]
Synonyms
Taclonex
    Click to Show/Hide
External Link
CID: 9832804
TTD: D0FW2A
 Compound Name ARQ-151 Phase 3 [23]
External Link
TTD: DST04F
 Compound Name IB-MECA Phase 3 [24]
Synonyms
152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide
    Click to Show/Hide
External Link
CID: 123683
TTD: D0Y6ZK
DrugBank: DB05511
 Compound Name E-0116 Phase 3 [25]
External Link
TTD: D0V8GT
 Compound Name 5-methoxypsoralen Phase 3 [26]
Synonyms
5-MOP
    Click to Show/Hide
External Link
CID: 2355
TTD: D0QR5G
DrugBank: DB12216
 Compound Name RAVAX Phase 3 [27]
External Link
TTD: D0Q4GL
 Compound Name MK-3222 Phase 3 [28]
External Link
TTD: D0P1ME
 Compound Name Serlopitant Phase 2 [6]
Synonyms
VPD-737; UNII-277V92K32B; CHEMBL447955; 860642-69-9; 277V92K32B; 3-((3aR,4R,5S,7aS)-5-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-fluorophenyl)hexahydro-1H-isoindol-2(3H)-yl)cyclopent-2-enone; Serlopitant [USAN:INN]; VPD 737; Serlopitant (USAN); SCHEMBL3183159; GTPL9280; mk-0594; FLNYCRJBCNNHRH-OIYLJQICSA-N; BDBM50277511; compound 17 (Jiang et al. 2009); DB12973; D09378; 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one
    Click to Show/Hide
External Link
CID: 23653789
TTD: D0CB2B
DrugBank: DB12973
 Compound Name M-518101 Phase 3 [29]
External Link
TTD: D0A8KX
 Compound Name ASP-015K Phase 3 [30]
Synonyms
Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A
    Click to Show/Hide
External Link
CID: 57928403
TTD: D06EIC
DrugBank: DB11708
 Compound Name Fumaric acid Phase 3 [31]
Synonyms
Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)
    Click to Show/Hide
External Link
CID: 444972
TTD: D03GOO
DrugBank: DB01677
 Compound Name Bimosiamose Phase 2a [32]
Synonyms
TBC 1269; TBC-1269
    Click to Show/Hide
External Link
CID: 9811353
TTD: D02AUB
DrugBank: DB06197
 Compound Name JNJ-77242113 Phase 2 [33]
Synonyms
JNJ-2113
    Click to Show/Hide
External Link
TTD: DY2GF8
 Compound Name PF-07038124 Phase 2 [34]
Synonyms
(R)-4-(5-(4-Methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; 2415085-44-6; 3-[(4R)-2-hydroxyoxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)pyridine; BDBM589740; CS-0433935; Example 4 [US2020108083A1]; GLXC-25702; GTPL11950; HY-144683; M6ZU548FWD; PF 07038124 [WHO-DD]; PF07038124; PF-07038124; Pyridine, 3-((4R)-2-hydroxy-1,2-oxaborolan-4-yl)-5-(4-methoxy-3-propoxyphenyl)-; UNII-M6ZU548FWD; US11559538, Example 4
    Click to Show/Hide
External Link
CID: 148293990
TTD: D81WBS
 Compound Name IR502 Phase 2 [35]
Synonyms
Zorcell
    Click to Show/Hide
External Link
TTD: D0Z1CZ
 Compound Name VTP-43742 Phase 2 [24]
External Link
CID: 118282339
TTD: D0VB4X
 Compound Name Bertilimumab Phase 2 [24]
Synonyms
CAT-213; ICo-008
    Click to Show/Hide
External Link
TTD: D0V9LY
 Compound Name LEO 90100 Phase 2 [36]
External Link
TTD: D0V5VR
 Compound Name PF-06700841 Phase 2 [24]
Synonyms
BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone
    Click to Show/Hide
External Link
CID: 118878093
TTD: D0V4DX
DrugBank: DB15003
 Compound Name LEO-32731 Phase 1 [37]
Synonyms
LP0058
    Click to Show/Hide
External Link
CID: 54765967
TTD: D0U9WS
 Compound Name Ascrolimus Phase 2 [38]
Synonyms
A-86281; ABT-281; ZK-248258
    Click to Show/Hide
External Link
CID: 9919023
TTD: D0SL8J
 Compound Name BMS-582949 Phase 2 [39]
Synonyms
623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; BMS582949 free base; PS 540446
    Click to Show/Hide
External Link
CID: 10409068
TTD: D0Q0AP
DrugBank: DB12696
 Compound Name BT-061 Phase 2 [40]
External Link
TTD: D0NQ0V
 Compound Name VB-201 Phase 2 [41]
External Link
CID: 45138527
TTD: D0N2IE
DrugBank: DB15259
 Compound Name MK-0873 Phase 2 [42]
Synonyms
MK-0873 (dermatological, psoriasis); MK-0873 (dermatological, psoriasis), Merck & Co
    Click to Show/Hide
External Link
CID: 9919680
TTD: D0M7CB
DrugBank: DB13029
 Compound Name GSK2982772 Phase 1 [24]
Synonyms
LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr
    Click to Show/Hide
External Link
CID: 77108121
TTD: D0LQ3L
 Compound Name PH-10 Phase 2 [24]
Synonyms
Rose Bengal sodium salt; Bengal Rose B sodium salt; CI Acid red 94; NCGC00159508-02; disodium 2,3,4,5-tetrachloro-6-(2,4,5,7-tetraiodo-3-oxido-6-oxoxanthen-9-yl)benzoate; DSSTox_CID_2814; AC1L1NH9; AC1MC45U; DSSTox_RID_76740; DSSTox_GSID_22814; DTXSID4022814; CHEMBL2359093; CTK8G2989; Rose bengal, Dye content 95 %; UWBXIFCTIZXXLS-UHFFFAOYSA-L; Tox21_111727; MFCD00005043; GT2559; AKOS015902615; AKOS024319604; MCULE-2782240614; CAS-632-69-9; Tetrachlorotetraiodofluorescein disodium salt; ST50411638; F000
    Click to Show/Hide
External Link
CID: 32343
TTD: D0L1VF
 Compound Name ANB-019 Phase 2 [43]
External Link
TTD: D0G4JC
 Compound Name IP10 C8 Phase 2 [44]
Synonyms
IP10C8
    Click to Show/Hide
External Link
TTD: D0E3HY
 Compound Name BMS-986020 Phase 1 [24]
Synonyms
GQBRZBHEPUQRPL-LJQANCHMSA-N; 1257213-50-5; AP-3152 free acid; UNII-38CTP01B4L; 38CTP01B4L; SCHEMBL344742; GTPL9498; EX-A866; MolPort-044-616-249; ZINC113624125; AKOS030631907; CS-5844; AS-35060; HY-100619; FT-0700148; J-690107; Cyclopropanecarboxylic acid, 1-(4'-(3-methyl-4-((((1R)-1-phenylethoxy)carbonyl)amino)-5-isoxazolyl)(1,1'-biphenyl)-4-yl)-; 1-{4'-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonyl
    Click to Show/Hide
External Link
CID: 49792850
TTD: D0D6ZW
DrugBank: DB14948
 Compound Name CMI-392 Phase 2 [45]
Synonyms
LDP-392; 3-[2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[trans-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzyl]-1-hydroxy-1-methylurea
    Click to Show/Hide
External Link
CID: 6918268
TTD: D0D5ZV
 Compound Name Santalum album Phase 2 [24]
External Link
TTD: D0C8KP
 Compound Name CT 327 Phase 2 [46]
External Link
TTD: D0B7OY
 Compound Name RVT-505 Phase 2 [6]
External Link
TTD: D0AF5P
 Compound Name Rambazole Phase 2 [10]
Synonyms
Talarozole; 201410-53-9; R-115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine; R115866; CHEMBL459505; C21H23N5S; Rambazole (TN); Talarozole (USAN/INN); Talarozole [USAN:INN]; R 115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine; Talarozole pound> SCHEMBL721201; CHEBI:102167; MolPort-018-666-712; SNFYYXUGUBUECJ-UHFFFAOYSA-N; BCP28256; BCP21218; BDBM50253810; 0328AB; AKOS005067289; DB13083; CS-1343; NCGC00378894-01; HY-14531; AX8224298; D09385; W-5674; MEN13510
    Click to Show/Hide
External Link
CID: 9799888
TTD: D0AA6Z
DrugBank: DB13083
 Compound Name Siplizumab Discontinued in Phase 2 [47]
Synonyms
Siplizumab (USAN/INN)
    Click to Show/Hide
External Link
TTD: D0A7NB
 Compound Name IMO-3100 Phase 2 [48]
External Link
TTD: D08OXU
 Compound Name LLL-3348 Phase 2 [49]
Synonyms
Desoris; LL-3348; Herbal anti-inflammatory (psoriasis), Lupin
    Click to Show/Hide
External Link
TTD: D08HGR
 Compound Name Elisidepsin Phase 2 [50]
Synonyms
Irvalec; Elisidepsin trifluoroacetate; PM-02734; Erbb3 tyrosine kinase receptor inhibitor (cancer), PharmaMar; Kahalalide therapy (solid tumor), PharmaMar
    Click to Show/Hide
External Link
CID: 9855343
TTD: D08GIM
 Compound Name Santalum Phase 2 [6]
External Link
TTD: D06OVF
 Compound Name Apo805K1 Phase 2 [51]
External Link
CID: 76318569
TTD: D06HQM
 Compound Name BTT-1023 Phase 2 [52]
Synonyms
SI-3106; SI-636; Fully human VAP-1 mAbs (inflammation), BioTie/Seikagaku; Fully human VAP-1 monoclonal antibody (inflammation), BioTie/Seikagaku; VAP-1 antibody (rheumatoid arthritis/psoriasis), BioTie
    Click to Show/Hide
External Link
TTD: D06GUG
 Compound Name BFH-772 Phase 2 [53]
Synonyms
NVP-BFH-772
    Click to Show/Hide
External Link
CID: 24756034
TTD: D04OTY
 Compound Name LL-4218 Phase 2 [54]
Synonyms
Desoside-P
    Click to Show/Hide
External Link
TTD: D04MYS
 Compound Name BIM23A760 Discontinued in Phase 3 [55]
Synonyms
Lonapalene; RS-43179; 91431-42-4; UNII-WIF31Q54NJ; WIF31Q54NJ; CHEMBL36648; Lonapalenum; Lonapaleno; Lonapalenum [Latin]; Lonapaleno [Spanish]; Lonapalene (USAN); Lonapalene [USAN:INN]; RS 43179; 6-Chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate; (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate; AC1L1KN9; SCHEMBL120134; ZINC1630; DTXSID00238563; IFWMVQUGSGWCRP-UHFFFAOYSA-N; HY-U00156; BDBM50004677; CS-7197; ZB000377; D04770; 6-chloro-1,4-diacetoxy-2,3-dimethoxynaphthalene
    Click to Show/Hide
External Link
CID: 56237
TTD: D04FNQ
 Compound Name AN0128 Phase 2 [56]
Synonyms
Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane
    Click to Show/Hide
External Link
CID: 11704019
TTD: D03VPJ
 Compound Name DPS-102 Phase 2 [57]
Synonyms
Non-steroidal anti-inflammatory (topical dermatological, scalp psoriasis), DermiPsor
    Click to Show/Hide
External Link
TTD: D02TYV
 Compound Name LEO 22811 Phase 2 [58]
External Link
TTD: D01FZX
 Compound Name E6201 Phase 2 [59]
Synonyms
novel MEK inhibitors
    Click to Show/Hide
External Link
CID: 10172827
TTD: D01CNB
DrugBank: DB11687
 Compound Name Fezakinumab Phase 2 [60]
Synonyms
Fezakinumab (IV), fezakinumab (SC), ILV-094 (IV), ILV-094 (SC), PF-5212367 (IV) PF-5212367(SC)
    Click to Show/Hide
External Link
TTD: D01AIN
 Compound Name NN-8226 Phase 2 [61]
Synonyms
NNC-109-0012; IL-20 monoclonal antibody (inflammation), Novo Nordisk; Anti-IL20 (inflammation), ZymoGenetics/Novo Nordisk; Anti-IL20mAb (RA), ZymoGenetics/Novo Nordisk; Anti-interleukin-20 (rheumatoid arthritis), ZymoGenetics/Novo Nordisk
    Click to Show/Hide
External Link
TTD: D00LGA
 Compound Name Lunacalcipol Phase 2 [62]
Synonyms
CTA-018; MT-2832; Lunacalcipol (intravenous, secondary hyperparathyroidism); Lunacalcipol (intravenous, secondary hyperparathyroidism), Cytochroma; Vitamin D analogs (secondary hyperparathyroidism), Johns Hopkins/Cytochroma; CTA-018 (intravenous, secondary hyperparathyroidism), Cytochroma; CYP24 inhibitors (intravenous, secondary hyperparathyroidism), Johns Hopkins/Cytochroma
    Click to Show/Hide
External Link
CID: 10672195
TTD: D00DYK
 Compound Name Dalazatide Phase 1b/2a [63]
Synonyms
Dalazatide [INN]; UNII-6U0259J807; 1081110-69-1; o-PHOSPHONO-L-Tyrosyl-2-(2-(2-aminoethoxy)ethoxy)acetyl(potassium channel toxin kappa-stichotoxin-shela stoichactis helianthus (caribbean sea anemone)) peptidamide; 6U0259J807
    Click to Show/Hide
External Link
CID: 86278334
TTD: D0OK4O
 Compound Name Debio-0824 Phase 1b/2a [63]
Synonyms
Shk-192; ShK analogs (Subcutaneous formulation, autoimmune disease), Kineta; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease); Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (Subcutaneous formulation, autoimmune disease), Airmid; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (injectable peptide, autoimmune disease), Davis; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease), Kineta One
    Click to Show/Hide
External Link
TTD: D01XEO
 Compound Name COVA322 Phase 1/2a [64]
External Link
TTD: D00BPH
 Compound Name AS-210 Phase 1/2 [65]
Synonyms
Psoraxine; AS-1001; AS-1002; AS-200; Psoriasis immunotherapy, Astralis/SkyePharma
    Click to Show/Hide
External Link
TTD: D0U8QC
 Compound Name ART621 Phase 1/2 [10]
External Link
TTD: D08KCK
 Compound Name JNJ-1459 Phase 1 [66]
External Link
TTD: DZ46KV
 Compound Name XCUR17 Phase 1 [6]
External Link
TTD: D0ZL5J
 Compound Name CM2489 Phase 1 [67]
External Link
TTD: D0W3JH
 Compound Name EDP1066 Phase 1 [6]
External Link
TTD: D0UD1J
 Compound Name BAY1834845 Phase 1 [6]
External Link
TTD: D0QQ7I
 Compound Name LEO-27989 Phase 1 [68]
External Link
TTD: D0QJ2K
 Compound Name SNA-125 Phase 1 [6]
External Link
TTD: D0Q0IM
 Compound Name ONS-3010 Phase 1 [24]
External Link
TTD: D0MI8Z
 Compound Name CC-90006 Phase 1 [6]
External Link
TTD: D0L5ZH
 Compound Name Pc4 Phase 1 [69]
Synonyms
Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC
    Click to Show/Hide
External Link
TTD: D0L2YF
 Compound Name PRX003 Phase 1 [24]
External Link
TTD: D0L0DA
 Compound Name JNJ-3534 Phase 1 [6]
External Link
TTD: D0K9YJ
 Compound Name BBI-6000 Phase 1 [6]
External Link
TTD: D0FY4J
 Compound Name PF-06263276 Phase 1 [70]
External Link
CID: 135567296
TTD: D0DK5X
 Compound Name ALX-0761 Phase 1 [71]
External Link
TTD: D0B5UH
 Compound Name ILV-095 Phase 1 [72]
Synonyms
PF-05212368, WAY-264095
    Click to Show/Hide
External Link
TTD: D0A9GI
 Compound Name ARN-6039 Phase 1 [24]
Synonyms
BOS172767
    Click to Show/Hide
External Link
TTD: D0A0ZW
 Compound Name LY3316531 Phase 1 [6]
External Link
TTD: D08FIB
 Compound Name SAFINGOL Phase 1 [73]
Synonyms
Kynac; Kynacyte; SPC-100270; Safingol < Rec INN; L-threo-Dihydrosphingosine; SPC-100271 (HCl); (2S,3S)-2-Aminooctadecane-1,3-diol
    Click to Show/Hide
External Link
CID: 3058739
TTD: D07CAQ
DrugBank: DB11924
 Compound Name BCT-194 Phase 1 [74]
External Link
TTD: D06CSK
 Compound Name SB414 Phase 1 [6]
External Link
TTD: D02UYM
 Compound Name AST-005 Phase 1 [6]
External Link
TTD: D02PTI
 Compound Name Quinazoline derivative 12 Patented [75]
Synonyms
PMID26936077-Compound-23
    Click to Show/Hide
External Link
CID: 60163336
TTD: D0EC3H
 Compound Name Quinazoline derivative 10 Patented [75]
Synonyms
PMID26936077-Compound-21
    Click to Show/Hide
External Link
CID: 6737869
TTD: D0CM5P
 Compound Name Quinazoline derivative 11 Patented [75]
Synonyms
PMID26936077-Compound-22
    Click to Show/Hide
External Link
CID: 60163203
TTD: D08ZEM
 Compound Name PMID27998201-Compound-5 Patented [76]
External Link
CID: 46202117
TTD: D05OIU
 Compound Name VX-148 Patented [77]
Synonyms
SCHEMBL12343182; BDBM248095; VX-148 (3)
    Click to Show/Hide
External Link
CID: 56603796
TTD: D00RJA
 Compound Name IRX-4310 Discontinued in Phase 3 [78]
Synonyms
AGN-194310; AGN-4310; ALRT-4310; LGD-4310; NRX-4310; RARa antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics; Retinoic acid receptor alpha antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics
    Click to Show/Hide
External Link
TTD: D0T0LE
 Compound Name Etarotene Discontinued in Phase 3 [79]
Synonyms
Ro-15-1570; Ro-15-1570/000
    Click to Show/Hide
External Link
CID: 6435463
TTD: D0FQ6O
 Compound Name KC706 Discontinued in Phase 2 [80]
External Link
TTD: D0Y2HH
 Compound Name VTP-201227 Discontinued in Phase 2 [81]
External Link
TTD: D0X6XF
 Compound Name IC-747 Discontinued in Phase 2 [82]
Synonyms
LFA-1 antagonists, ICOS/Biogen
    Click to Show/Hide
External Link
TTD: D0W7GH
 Compound Name CRx-191 Discontinued in Phase 2 [83]
External Link
TTD: D0VA2I
 Compound Name LAS-37779 Discontinued in Phase 2 [84]
External Link
TTD: D0V2CN
 Compound Name TU-2100 Discontinued in Phase 2 [85]
External Link
CID: 4342838
TTD: D0P3TF
 Compound Name ASF-1075 Discontinued in Phase 2 [86]
External Link
TTD: D0KY4O
 Compound Name BMS-587101 Discontinued in Phase 2 [87]
Synonyms
BMS-688521
    Click to Show/Hide
External Link
CID: 11635371
TTD: D0GT8W
 Compound Name R-68151 Discontinued in Phase 2 [88]
Synonyms
1-Ethyl-3-{4-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-phenyl}-5,5-dimethyl-2-thioxo-imidazolidin-4-one; 5-Lipoxygenase-In-1; R 68151; CHEMBL85599; 138331-04-1; AC1L30HG; SCHEMBL13696698; DTXSID10160583; BDBM50006793; HY-U00308; CS-7300; (1-Ethyl-3(4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-5-dimethyl)-2-thioxo-4-imidazolidinone; 1-ethyl-3-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-5,5-dimethyl-2-sulfanylideneimidazolidin-4-one; M55551
    Click to Show/Hide
External Link
CID: 132150
TTD: D0G5GJ
 Compound Name T487 Discontinued in Phase 2 [89]
Synonyms
AC1MVK5U; 2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methyl-ethanamine; 2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methylethanamine
    Click to Show/Hide
External Link
CID: 12896
TTD: D0E6DI
 Compound Name SDZ-LAP-977 Discontinued in Phase 2 [90]
Synonyms
SDZ-281-977
    Click to Show/Hide
External Link
CID: 9818362
TTD: D0D5CJ
 Compound Name VML-262 Discontinued in Phase 2 [91]
Synonyms
Marigold compound (topical, psoriasis), University of Strathclyde; VAN-10-4 (topical, psoriasis), University of Strathclyde/Vanguard Medica
    Click to Show/Hide
External Link
TTD: D0CC1Y
 Compound Name SB-201993 Discontinued in Phase 2 [92]
Synonyms
UNII-4TWC061LPM; 4TWC061LPM; CHEMBL422598; SB 201993; AC1O5KJ7; SCHEMBL1893839; SCHEMBL1893835; sb201993; BDBM50037385; (E)-3-((((6-(2-Carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid; L009321; 3-[[6-[(E)-3-hydroxy-3-oxoprop-1-enyl]-5-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]methylsulfanylmethyl]benzoic acid; 3-{6-((E)-2-Carboxy-vinyl)-5-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid; Benzoic acid, 3-((((6-(2-carboxyethenyl)-5-((8-(4-m
    Click to Show/Hide
External Link
CID: 6435820
TTD: D0B6JV
 Compound Name PVAC Discontinued in Phase 2 [93]
Synonyms
DDMV, Corixa/ Genesis/ Zenyaku Kogyo; Delipidated, deglycolipidated Mycobacterium vaccae, Corixa/ Genesis/ Zenyaku Kogyo
    Click to Show/Hide
External Link
TTD: D0B1NA
 Compound Name Tisocalcitate Discontinued in Phase 2 [94]
Synonyms
SH-597; ZK-156942; Calcitriol analog (topical formulation), Schering AG
    Click to Show/Hide
External Link
CID: 9913924
TTD: D07BDY
 Compound Name BAL-2299 Discontinued in Phase 2 [95]
Synonyms
Cyclohexanediol, Basilea
    Click to Show/Hide
External Link
TTD: D07AIE
 Compound Name Atocalcitol Discontinued in Phase 2 [96]
Synonyms
KH-1650
    Click to Show/Hide
External Link
CID: 6445225
TTD: D06SBK
 Compound Name FPL-64170 Discontinued in Phase 2 [97]
External Link
TTD: D04QVN
 Compound Name BIRT 2584 Discontinued in Phase 2 [87]
Synonyms
QSNSVPRLHYSSQG-AMXDTQDGSA-N; UNII-24P4O1J71F; 24P4O1J71F; SCHEMBL4017930; BIRT-2584; (S)-2-[(R)-7-(3,5-Dichloro-phenyl)-5-methyl-6-oxo-5-(4-trifluoromethoxy-benzyl)-6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide; 688756-00-5
    Click to Show/Hide
External Link
CID: 10348691
TTD: D01WQO
 Compound Name SB 235699 Discontinued in Phase 1 [98]
Synonyms
4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; VK-19911; CHEMBL279416; UNII-NP7J08ZRYY; NP7J08ZRYY; 180869-32-3; SCHEMBL140202; HEP 689; sb235699; BDBM50099331; SB-235699; 4-(5-(4-Fluorophenyl)-3-(4-piperidyl)imidazol-4-yl)pyridine; Pyridine, 4-(4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl)-
    Click to Show/Hide
External Link
CID: 9797240
TTD: D0W0AM
 Compound Name PD-153035 Discontinued in Phase 1 [99]
Synonyms
183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo
    Click to Show/Hide
External Link
CID: 4705
TTD: D0Q7HO
 Compound Name ALS-00T2-0501 Discontinued in Phase 1 [100]
Synonyms
TNF Blocker (Intradel, psoriasis), Apollo Life Sciences; TNF Blocker (TransD, psoriasis), Apollo Life Sciences; TNF Blocker (transdermal cream, psoriasis), Apollo Life Sciences; TNF receptor antagonist (Intradel, psoriasis), Apollo Life Sciences; TNF receptor antagonist (TransD, psoriasis), Apollo Life Sciences; TNF receptor antagonist (transdermal cream, psoriasis), Apollo Life Sciences
    Click to Show/Hide
External Link
TTD: D05NUT
 Compound Name CCX-832 Discontinued in Phase 1 [101]
Synonyms
ChemR2 receptor antagonist (inflammation), ChemoCentryx/GlaxoSmithKline
    Click to Show/Hide
External Link
TTD: D04HZX
 Compound Name CLS008 Application submitted [6]
External Link
TTD: D0A6SD
 Compound Name DYV024 Preclinical [102]
External Link
TTD: DPW1K9
 Compound Name VCB102 Preclinical [103]
External Link
TTD: DG07UD
 Compound Name RAP-160 Preclinical [104]
External Link
TTD: D05VOP
 Compound Name ATL-1101 Preclinical [105]
External Link
TTD: D01QKD
 Compound Name Hu Dreg 55 Terminated [106]
Synonyms
SMART Anti-L-Selectin
    Click to Show/Hide
External Link
TTD: D0Z0HS
 Compound Name DB-200 Terminated [107]
Synonyms
DB-200 series (topical, psoriasis); CPT-1 inhibitor (topical, psoriasis), DARA; DB-200 series (topical, psoriasis), DARA BioSciences
    Click to Show/Hide
External Link
TTD: D0SG0N
 Compound Name MOR-102 Terminated [108]
Synonyms
MOR-101; MOR-101); ICAM-1 antibody (inflammation), MorphoSys
    Click to Show/Hide
External Link
TTD: D0M8JF
 Compound Name YP-008 Terminated [109]
Synonyms
RPL-228; Cyclopentenone prostaglandin mimetic (PGM) (topical, psoriasis), York Pharma; Natural-defence-prostanoid mimetic (topical, psoriasis), York Pharma
    Click to Show/Hide
External Link
TTD: D0L8TL
 Compound Name CRA-028129 Terminated [110]
External Link
TTD: D0K0IW
 Compound Name SB-209247 Terminated [111]
Synonyms
Ticolubant; LTB4 antagonist, SB
    Click to Show/Hide
External Link
CID: 6441619
TTD: D0G7SP
 Compound Name AD-177 Terminated [112]
External Link
TTD: D03JMN
 Compound Name R348 Terminated [10]
External Link
CID: 68254
TTD: D01XEQ
 Compound Name FM-301 Investigative [113]
External Link
TTD: D0U5SU
 Compound Name AZ-17 Investigative [113]
External Link
TTD: D0K0CK
 Compound Name Hairpin RNA Investigative [113]
Synonyms
Hairpin RNA (psoriasis); Hairpin RNA (psoriasis), SomaGenics; ShRNA (psoriasis), SomaGenics
    Click to Show/Hide
External Link
TTD: D0IY2B
 Compound Name KM-133 Investigative [113]
External Link
CID: 71605071
TTD: D0IC6D
DrugBank: DB12187
 Compound Name PU-2049 Investigative [113]
Synonyms
N-[2-(5-Methoxyindol-3-yl)ethyl]-10-undecenamide; 5-Methoxy-N-(10-undecenoyl)tryptamine
    Click to Show/Hide
External Link
TTD: D0I8QF
 Compound Name ASB-16165 Investigative [113]
Synonyms
PDE7 inhibitor (topical, psoriasis), Asubio
    Click to Show/Hide
External Link
CID: 25255436
TTD: D0C3ET
 Compound Name Amphiregulin targeting human mabs Investigative [113]
Synonyms
Amphiregulin targeting human mAbs (psoriasis)
    Click to Show/Hide
External Link
TTD: D0B1CJ
 Compound Name GSK-2263167 Investigative [113]
Synonyms
S1P1 agonists (psoriasis), GlaxoSmithKline; Sphingosine 1 phosphate-1 agonists (psoriasis); Sphingosine 1 phosphate-1 agonists (psoriasis), GlaxoSmithKline
    Click to Show/Hide
External Link
TTD: D08UDB
 Compound Name DPS-151 Investigative [113]
External Link
TTD: D08UAT
 Compound Name LPD-1050 Investigative [113]
External Link
TTD: D08EQQ
 Compound Name CXCL8 Investigative [113]
Synonyms
Interleukin-8; CHEMBL411250; IL-8
    Click to Show/Hide
External Link
CID: 74974005
TTD: D07PHS
 Compound Name DM-512 Investigative [113]
External Link
TTD: D06TAR
 Compound Name KIN-4050 Investigative [113]
Synonyms
ERK inhibitor (topical, psoriasis), Kinentia; MAP kinase inhibitor (topical, psoriasis), Kinentia
    Click to Show/Hide
External Link
TTD: D06MTH
 Compound Name Ankinara Investigative [114]
External Link
TTD: D05TZJ
 Compound Name BL-7020 Investigative [113]
Synonyms
Recombinant IGFBP (intradermal, psoriasis), BioLineRx
    Click to Show/Hide
External Link
TTD: D04FHY
 Compound Name X-083-NAB Investigative [113]
Synonyms
NATHMAB (psoriasis/Crohns disease/type 1 diabetes), XBiotech; Unspecified cytokine receptor antagonist (human monoclonal antibody, psoriasis/Crohns disease/type 1 diabetes), XBiotech
    Click to Show/Hide
External Link
TTD: D04ASA
 Compound Name LEO-90110 Investigative [113]
External Link
TTD: D01ATS
References
Ref 1 N(6)-methyladenosine-modified long non-coding RNA AGAP2-AS1 promotes psoriasis pathogenesis via miR-424-5p/AKT3 axis. J Dermatol Sci. 2022 Jan;105(1):27-36. doi: 10.1016/j.jdermsci.2021.11.007. Epub 2021 Nov 18.
Ref 2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030730)
Ref 3 ClinicalTrials.gov (NCT00852670) ACT-128800 in Psoriasis. U.S. National Institutes of Health.
Ref 4 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761244.
Ref 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
Ref 6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 7 ClinicalTrials.gov (NCT04036435) Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis.. U.S. National Institutes of Health.
Ref 8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 9 Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007 May;19(3):238-45.
Ref 10 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. doi: 10.1517/14728210902771334.
Ref 11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6952).
Ref 12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6885).
Ref 13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2780).
Ref 14 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009048.
Ref 15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7372).
Ref 16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7598).
Ref 17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7540).
Ref 18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6593).
Ref 19 ClinicalTrials.gov (NCT01098734) Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream. U.S. National Institutes of Health.
Ref 20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2778).
Ref 21 ClinicalTrials.gov (NCT01373567) A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis. U.S. National Institutes of Health.
Ref 22 ClinicalTrials.gov (NCT00924950) Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis. U.S. National Institutes of Health.
Ref 23 ClinicalTrials.gov (NCT04746911) Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216). U.S. National Institutes of Health.
Ref 24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 25 Biopharmaceutical Research Companies Are Developing Nearly 300 Medicines to Treat Diseases of the Skin. MEDICINES IN DEVELOPMENT FOR Skin Diseases 2011.
Ref 26 ClinicalTrials.gov (NCT00533195) Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis. U.S. National Institutes of Health.
Ref 27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006246)
Ref 28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8093).
Ref 29 ClinicalTrials.gov (NCT01989429) Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients. U.S. National Institutes of Health.
Ref 30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8315).
Ref 31 Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. doi: 10.1517/14728214.13.3.465.
Ref 32 Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
Ref 33 ClinicalTrials.gov (NCT05223868) A Phase 2b Multicenter, Randomized, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis. U.S.National Institutes of Health.
Ref 34 ClinicalTrials.gov (NCT05375955) A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSE LEVELS OF PF-07038124 OINTMENT FOR 12 WEEKS IN PARTICIPANTS 12 YEARS AND OLDER AND WITH MILD-TO-MODERATE ATOPIC DERMATITIS OR MILD-TO-SEVERE PLAQUE PSORIASIS. U.S.National Institutes of Health.
Ref 35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008880)
Ref 36 ClinicalTrials.gov (NCT01600222) Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris. U.S. National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT01310049) LEO 32731 - A Study in Healthy Male Subjects. U.S. National Institutes of Health.
Ref 38 Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation. 2014 Mar 27;97(6):636-41.
Ref 39 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7838).
Ref 40 ClinicalTrials.gov (NCT01072383) Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis. U.S. National Institutes of Health.
Ref 41 ClinicalTrials.gov (NCT01001468) Study to Assess VB-201 in Patients With Psoriasis. U.S. National Institutes of Health.
Ref 42 ClinicalTrials.gov (NCT00132730) An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005). U.S. National Institutes of Health.
Ref 43 ClinicalTrials.gov (NCT03619902) A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis (GPP). U.S. National Institutes of Health.
Ref 44 Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61.
Ref 45 Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.
Ref 46 ClinicalTrials.gov (NCT01808157) A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis. U.S. National Institutes of Health.
Ref 47 Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.
Ref 48 ClinicalTrials.gov (NCT01622348) Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis. U.S. National Institutes of Health.
Ref 49 Clinical pipeline report, company report or official report of Lupin Ltd.
Ref 50 First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug;33(4):901-10.
Ref 51 ClinicalTrials.gov (NCT01483924) Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis. U.S. National Institutes of Health.
Ref 52 ClinicalTrials.gov (NCT02239211) A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis. U.S. National Institutes of Health.
Ref 53 ClinicalTrials.gov (NCT01449591) Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients. U.S. National Institutes of Health.
Ref 54 Clinical pipeline report, company report or official report of Lupin Ltd.
Ref 55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003802)
Ref 56 Clinical pipeline report, company report or official report of Anacor Pharmaceuticals.
Ref 57 ClinicalTrials.gov (NCT01368887) Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis. U.S. National Institutes of Health.
Ref 58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028044)
Ref 59 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7836).
Ref 60 ClinicalTrials.gov (NCT01941537) Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis. U.S. National Institutes of Health.
Ref 61 ClinicalTrials.gov (NCT02097264) A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. U.S. National Institutes of Health.
Ref 62 ClinicalTrials.gov (NCT01453634) Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018). U.S. National Institutes of Health.
Ref 63 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. doi: 10.1038/s41573-019-0013-8.
Ref 64 ClinicalTrials.gov (NCT02243787) Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis
Ref 65 ClinicalTrials.gov (NCT02360358) Autologous Skin Substitute for Chronic Leg/Foot Ulcers.. U.S. National Institutes of Health.
Ref 66 Clinical pipeline report, company report or official report of JOHNSON & JOHNSON
Ref 67 Clinical pipeline report, company report or official report of CalciMedica (2011).
Ref 68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033794)
Ref 69 Association between the photodynamic loss of Bcl-2 and the sensitivity to apoptosis caused by phthalocyanine photodynamic therapy. Photochem Photobiol. 2003 Jul;78(1):1-8.
Ref 70 ClinicalTrials.gov (NCT01981681) A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects. U.S. National Institutes of Health.
Ref 71 ClinicalTrials.gov (NCT02156466) Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
Ref 72 ClinicalTrials.gov (NCT01010542) Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects. U.S. National Institutes of Health.
Ref 73 ClinicalTrials.gov (NCT00084812) Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
Ref 74 ClinicalTrials.gov (NCT01539915) Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients. U.S. National Institutes of Health.
Ref 75 Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
Ref 76 Cathepsin B and L inhibitors: a patent review (2010 - present). Expert Opin Ther Pat. 2017 Jun;27(6):643-656. doi: 10.1080/13543776.2017.1272572. Epub 2016 Dec 23.
Ref 77 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013965)
Ref 78 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009573)
Ref 79 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003576)
Ref 80 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023346)
Ref 81 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022961)
Ref 82 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015378)
Ref 83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025635)
Ref 84 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022894)
Ref 85 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013307)
Ref 86 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024080)
Ref 87 Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
Ref 88 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003630)
Ref 89 Clinical pipeline report, company report or official report of ChemoCentryx.
Ref 90 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004738)
Ref 91 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008645)
Ref 92 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003335)
Ref 93 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011840)
Ref 94 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018814)
Ref 95 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016543)
Ref 96 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014844)
Ref 97 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005063)
Ref 98 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012315)
Ref 99 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005268)
Ref 100 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023971)
Ref 101 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025006)
Ref 102 Clinical pipeline report, company report or official report of Dyve Biosciences
Ref 103 Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317. doi: 10.1038/s41573-018-0008-x.
Ref 104 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036946)
Ref 105 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020853)
Ref 106 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004232)
Ref 107 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026687)
Ref 108 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017213)
Ref 109 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026448)
Ref 110 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022029)
Ref 111 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006734)
Ref 112 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015044)
Ref 113 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 114 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.